home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 10/25/22

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference

FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Chief Medical Officer, Dr. Lauren V. W...
PDSB - PDS Biotech: Strong Data Indicate Further Upside

Summary As it successfully pivoted into immuno-oncology, PDS is making big waves in this therapeutic development space. The premier drug development platform (Versamune) already generated extremely robust early data for various cancers. PDS is poised to present additional clin...

PDSB - PDS Biotech to Present at the LD Micro Main Event XV

FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will present at the LD ...

PDSB - PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

FLORHAM PARK, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that an abstract reporting on preclinical s...
PDSB - PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022

FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB),  a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced it will host a Head and Neck Canc...

PDSB - PDS Biotech stock soars 14% as PDS0101 shows promise vs HPV-positive cancers in interim trial data

PDS Biotechnology ( NASDAQ: PDSB ) stock rose ~14% on Oct. 11 after the company reported interim data from a phase 2 trial of PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers. The company said the study is evaluating PD...

PDSB - PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

FLORHAM PARK, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced expanded interim data in the Phase 2 clinic...
PDSB - PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that PDS Biotech granted nonstatutory stock...

PDSB - Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing CAGR. Cervical Cancer is a cancer arising from the cervix w...

PDSB - PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022

FLORHAM PARK, N.J., Oct. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that two abstracts reporting the result...
Previous 10 Next 10